People in the Friedreich’s ataxia (FA) community await the possibility of gene therapies for their disease, with many saying…
Articles by Marisa Wexler, MS
Hot topics of the Nov. 1 webinar included the challenges of living with Friedreich's ataxia, strategies for success, and the recent "game-changing" therapy approval. Read more about the highlights here.
Therapies that aid mitochondria, cellular organelles responsible for producing most of the energy needed by cells, may help with physical…
Analyzing patients’ voices using machine learning may help to identify Friedreich’s ataxia (FA) and differentiate it from other neurological…
People with Friedreich’s ataxia who were treated with Skyclarys (omaveloxolone) in the MOXIe trial and its extension for…
Treatment with interferon gamma (IFN-gamma), an immune signaling molecule, helped to protect against damage in a cellular model of…
In a deal worth more than $7 billion, Biogen is acquiring Reata Pharmaceuticals, the developers of…
The U.S. Food and Drug Administration (FDA) has greenlighted a request by Larimar Therapeutics to test a 50 mg…
Measuring abnormalities in the neurological circuits the brain uses to make sense of sound could be a useful way to…
Fredrich’s ataxia (FA) impairs the regulation of hundreds of genes in muscle cells, resulting in reduced activity in those…